Skip to main content
SpringerLink
Log in

A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase®), a Novel Ribonuclease in Patients with Metastatic Kidney Cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Ranpirnase (Onconase®) is the firstribonuclease to enter cancer clinicaltrials. In prior phase II trials,responses were seen in mesothelioma andother solid tumors. This phase II trialtested ranpirnase (480 μg/m2/w) in14 patients with refractory advanced renalcell cancer. The median performance statuswas zero and the median age was 55. Allpatients had prior immunotherapy and threehad prior chemotherapy. No responses wereseen in 14 patients. The median survivalfrom on study was 16 months (range two to28 months). At this dose and scheduleranpirnase has minimal activity inmetastatic renal cell cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vogelzang NJ, Stadler WM: Kidney cancer. The Lancet 352: 1691–1696, 1998

    Google Scholar 

  2. Bukowski RM: Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80(7): 1198–1220, 1997

    Google Scholar 

  3. Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, Rubinstein L, Louie A, Mier JW, Gucalp R, et al: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 11: 661–670, 1993

    Google Scholar 

  4. Atzpodien J, Lopez Hanninen E, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, Metzner B, Illiger HJ, Jakse G, Niesel T, et al: Multi-institutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13(2): 497–501, 1995

    Google Scholar 

  5. Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Sosman J, Lotze M, Gordon M, Logan T, Mier J: Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Cancer J Sci Am, 3Suppl 1: S73–78, 1997

    Google Scholar 

  6. Vogelzang NJ, Lipton A, Figlin RA: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial. J Clin Oncol 11(9): 1809–1816, 1993

    Google Scholar 

  7. Stadler WM, Kuzel T, Dumas M, Vogelzang NJ: Multi-center phase II trial of interleukin-2, interferon-β, and 13-cis-retinoic acid in patients with metastatic renal cell carcinoma. J Clin Oncol 16(5): 1820–1825, 1998

    Google Scholar 

  8. Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13(8): 1950–1957, 1995

    Google Scholar 

  9. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17(9): 2859–2867, 1999

    Google Scholar 

  10. Medical Research Council Renal Cancer Collaborators: Interferon-β and survival in metastatic renal carcinoma: Early results of a randomized controlled trial. Lancet 353: 14–17, 1999

    Google Scholar 

  11. Negrier S, Escudier B, Lasset C, Douillard J-Y, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T for the Groupe Francais D=Immunotherapie: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. New Engl J Med 338(18): 1272–1278, 1998

    Google Scholar 

  12. Tippin DB, Reeves W, Vogelzang NJ: Diagnosis and treatment of leptomeningeal metastases in a patient with renal carcinoma responding to 5FU and Gemcitabine. J Urol 162(1): 155–156, 1999

    Google Scholar 

  13. Stadler WM, Dumas M, Flickinger S, Wade J, Vokes EE, Vogelzang NJ: Gemcitabine (GEM) and 5-Fluorouracil (5FU) in metastatic renal carcinoma (RC): A University of Chicago phase II consoritum study. Proc Amer Soc Clin Oncol, 18: 332a, 1999

    Google Scholar 

  14. Rini BI, Vogelzang NJ, Dumas MC, Wade JL, Taber DA, Stadler WM: A phase II trial of weekly intravenous gemcitabine with continuous infusion 5-fluorouracil (5FU) in patients with metastatic renal cell cancer. J Clin Onc, in press, 2001

  15. Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Brockstein BE, Stadler WM, Ratain MJ, Vokes EE: Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal Cancer. Clin Canc Res 4: 929–934, 1998

    Google Scholar 

  16. Stadler WM, Vogelzang NJ, Hoffman P, Arrietta R, Masters G, Fishkin P, Gibbons J, Lad TE, Vokes E: CI-980 in renal cell and non-small cell lung cancer: Multi-institutional trials from the University of Chicago phase II consortium. Cancer Therapeutics 1(5): 318–320, 1998

    Google Scholar 

  17. Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ: Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 17(8): 2541–2545, 1999

    Google Scholar 

  18. Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM: Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: Results of two Phase II clinical trials. Cancer 88(6): 1317–1324, 2000

    Google Scholar 

  19. Rini BI, Selk LM, Vogelzang NJ: Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Canc Res 5: 2766–2772, 1999

    Google Scholar 

  20. Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K: Cytostatic and cytotoxic effects of Pannon (P-30 Protein) a novel anti-cancer agent. Cell Tissue Kinet 21: 169–182, 1988

    Google Scholar 

  21. Mikulski SM, Ardelt W, Shogen K, Bernstein EH, Menduke H: Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J Natl Cancer Inst 82: 151–153, 1990

    Google Scholar 

  22. Ardelt W, Mikulski SM, Shogen K: Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases. J Biol Chem 266: 245–251, 1991

    Google Scholar 

  23. Mosimann SC, Johns KL, Ardelt W, Mikulski SM, Shogen K, James MN: Comparative molecular modeling and crystallization of P-30 Protein: A novel anti-tumor protein of Rana pipiens oocytes and early embryos. Prot Struct Funct Gen 14: 392–400, 1992

    Google Scholar 

  24. Mosimann SC, Ardelt W, James MNG: Refined 1.7 X-ray crystallographic structure of P-30 protein, an amphibian ribonuclease with anti-tumor activity. J Mol Biol 236: 1141–1153, 1994

    Google Scholar 

  25. Mikulski SM, Viera A, Ardelt W, Menduke H, Shogen K: Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/ cytotoxic effects of P-30 Protein, a novel protein possessing anti-tumor activity. Cell Tissue Kinet 23: 237–246, 1990

    Google Scholar 

  26. Rybak SM, Pearson JW, Fogler WE, Volker K, Spence SE, Newton DL, Mikulski SM, Ardelt W, Riggs CW, Kung HF, Longo DL: Enhancement of vincristine cytotoxicity in drugresistant cells by simultaneous treatment with Onconase®, an antitumor ribonuclease. J Natl Cancer Inst 88(11): 747–753, 1996

    Google Scholar 

  27. Iordanov MS, Ryabinina OP, Wong J, Dinh T-H, Newton DL, Rybak SM, Magun BE: Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: Evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 60: 1983–1994, 2000

    Google Scholar 

  28. Onconase® Investigator's Brochure, 1999. ALFACELL Corporation, Bloomfield, NJ

  29. Mikulski SM, Grossman AM, Carter PW, et al.: Phase I human clinical trial of Onconase® (P-30 Protein) administered intravenously on a weekly schedule in cancer patients with solid tumors. Int J Oncol 3: 57–64, 1993

    Google Scholar 

  30. Mikulski SM, Chun HG, Mittelman A, Panella T, Puccio CA, Shogen K, Costanzi JJ: Relationship between response rate and median survival in patients with advanced non-small cell lung cancer: Comparison on Onconase® with other anticancer agents. Int J Onc 6: 889–897, 1995

    Google Scholar 

  31. Mittelman A, Puccio C, Chun H, Costanzi J, Panella T, Coombe N, Shogen K, Mikulski S: A new anti-cancer Rnase (Onconase® ): Preliminary results in patients with breast cancer. Presented at the 21st meeting of the International Association for Breast Cancer Research, Paris, France, July 3, 1996

  32. Taub RN, Keohan ML, Vogelzang NJ, Costanzi J, Chun H, Mittelman A, Panella T, McCachren S, Puccio C, Shogen K, Fine R, Mikulski SM: Phase II trial of Onconase® in patients (PTS) with advanced malignant mesothelioma (MM): Analysis of survival. Proc Amer Soc Clin Oncol, 18: 524a, 1999

    Google Scholar 

  33. Dumas MC, Stadler W, Mikulski S, Vogelzang NJ: Phase II clinical trial of weekly intravenous Onconase® (ONC) in patients (PTS) with metastatic renal cell carcinoma (RCC).Proc Amer Soc Clin Oncol, 17: 330a, 1998

    Google Scholar 

  34. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8): 2530–2540, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Research Center, University of Chicago, USA

    Nicholas J. Vogelzang & Walter M. Stadler

  2. Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA

    Nicholas J. Vogelzang, Walter M. Stadler & Mary C. Dumas

  3. Alfacell Corp., Bloomfield, NJ, USA

    Stanislaw M. Mikulski

Authors
  1. Nicholas J. Vogelzang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mebea Aklilu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Walter M. Stadler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mary C. Dumas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stanislaw M. Mikulski
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vogelzang, N.J., Aklilu, M., Stadler, W.M. et al. A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase®), a Novel Ribonuclease in Patients with Metastatic Kidney Cancer. Invest New Drugs 19, 255–260 (2001). https://doi.org/10.1023/A:1010633004157

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010633004157

Search

Navigation